Status: Not yet recruiting
A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
This is a Phase I/II, single-arm, open-label, multicenter clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM). The study aims to evaluate the safety, tolerability, efficacy, cellular kinetics, and immunogenicity of CT0596.
Participants needed: 68
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: UCARsgen Biotech LimitedUpdated: Aug 12, 2026Locations: 2
Eligibility criteria
Voluntarily participate in the trial; fully understand and sign the informed con... [+7]
Pregnant or lactating women. [+18]